Table 4.
SIR of second primary cancer by type of first primary cancer and age group at first diagnosis
| Age group at first diagnosis | ||||||
|---|---|---|---|---|---|---|
| 15–49 years | 50–64 years | 65 years and over | ||||
| First primary cancer | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) | Obs. | SIR (95% CI) |
| Head/Neck/Larynx | 42 | 2.35 (1.69–3.17) | 189 | 2.21 (1.91–2.55) | 103 | 1.34 (1.10–1.63) |
| Stomach | 8 | 1.14 (0.49–2.25) | 43 | 0.92 (0.66–1.24) | 117 | 0.88 (0.72–1.05) |
| Colon/Rectum | 29 | 1.17 (0.78–1.68) | 200 | 1.03 (0.89–1.18) | 385 | 0.83 (0.75–0.92) |
| Lung | 13 | 1.31 (0.70–2.25) | 83 | 1.13 (0.90–1.40) | 90 | 0.93 (0.74–1.14) |
| Melanoma | 54 | 1.18 (0.89–1.54) | 88 | 0.89 (0.71–1.10) | 98 | 0.88 (0.71–1.07) |
| Breast | 70 | 0.79 (0.62–1.00) | 227 | 0.89 (0.78–1.02) | 283 | 0.77 (0.68–0.87) |
| Cervix | 43 | 1.56 (1.13–2.11) | 33 | 1.28 (0.88–1.80) | 26 | 1.32 (0.86–1.93) |
| Endometrium | 11 | 1.21 (0.60–2.16) | 67 | 1.06 (0.82–1.35) | 99 | 1.07 (0.87–1.31) |
| Ovary | 15 | 1.72 (0.96–2.83) | 26 | 1.09 (0.71–1.59) | 31 | 0.93 (0.63–1.31) |
| Prostate | 15 | 1.10 (0.62–1.81) | 326 | 0.66 (0.59–0.74) | 776 | 0.68 (0.63–0.73) |
| Bladder | 15 | 1.65 (0.93–2.73) | 126 | 1.41 (1.18–1.68) | 220 | 1.07 (0.93–1.22) |
| Kidney | 21 | 1.54 (0.96–2.36) | 106 | 1.35 (1.10–1.63) | 119 | 1.12 (0.93–1.34) |
| Thyroid gland | 23 | 1.05 (0.66–1.57) | 53 | 1.49 (1.12–1.95) | 43 | 1.37 (0.99–1.84) |
| NHL high/low | 10 | 1.24 (0.59–2.27) | 45 | 1.29 (0.94–1.73) | 56 | 1.15 (0.87–1.50) |
| CLL/ALL | 3 | 1.86 (0.38–5.44) | 14 | 0.71 (0.39–1.19) | 39 | 1.11 (0.79–1.52) |
| All cancers combined | 447 | 1.24 (1.12–1.36) | 1784 | 1.02 (0.97–1.07) | 2718 | 0.85 (0.82–0.89) |
Obs. Observed number of second primary cancers, SIR standardized incidence ratio, CI confidence interval, NHL non-Hodgkin Lymphoma, CLL chronic lymphatic leukaemia, ALL acute lymphatic leukaemia
SIRs shown in normal bold fond indicate significantly increased risk; SIRs shown in bold italics indicate significantly decreased risk